Pelitinib ≥98%|CAS:257933-82-7 |5 mg|10 mg|25 mg

EKB-569|Pelitinib is an irreversible EFGR inhibitor that exhibits anticancer chemotherapeutic benefit in the treatment of non-small cell lung cancer (NSCLC) and other solid tumor cancers. In vitro, pelitinib inhibits NF- B, inhibiting transcription of TERT and telomerase activity. Pelitinib also decreases phosphorylation of Akt and ERK and induces cell cycle arrest in vitro. |C24H23ClFN5O2|467.92|White Powder|Ambient|Insoluble in water. Soulble in DMSO (≥13 mg/mL).